A prostate cancer study24 found that patients with PTEN mutations in tumour tissue had higher Positron Emission Tomography‐Computed Tomography (PET‐CT) positivity rates in lesions, indirectly indicating differences in tumour burden. This evidence concerns the gene PTEN and prostate cancer.